Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
This review provides an overview of the evidence related to the role of dopamine deficiency in the pathogenesis of positive and negative schizophrenic symptoms and to the therapeutic use of amisulpride in this indication. It includes concepts of human neurobiology and neuropharmacology and their application to clinical medicine, as well as the presentation of the clinical evidence on the therapeutic efficacy and safety of amisulpride in schizophrenia, highlighting dosage issues.
Kasper
Siegfried
S
Department of General Psychiatry, University of Vienna, Vienna, Austria. sk@akh-wien.ac.at
D000077582:Amisulpride; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000096:biosynthesis / Q000172:deficiency*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051381:Rats; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride; D004298:Dopamine